Detalhe da pesquisa
1.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
2.
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Haematologica
; 103(8): e356-e359, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519866
3.
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood Adv
; 7(15): 3936-3945, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026799
4.
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Leukemia
; 35(6): 1597-1609, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32934355
5.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Lancet Haematol
; 6(9): e470-e479, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31324600
6.
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
J Clin Oncol
; 26(16): 2725-31, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18427151